KWKaixue Wen

Kaixue Wen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kaixue Wen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Ningning He

    Chinese Academy of Medical Sciences & Peking Union Medical College

    2 shared publications
  • Chang Xu

    Institute of Radiation Medicine Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China

    1 shared publication
  • Chengbin Liu

    Shandong Second Medical University

    1 shared publication
  • Feifei Ma

    Shandong Second Medical University

    1 shared publication
  • Hao Sun

    Shandong First Medical University & Shandong Academy of Medical Sciences

    1 shared publication
  • Hongxia Guo

    Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, China

    1 shared publication

Latest Publications

  • Open Access

    Exosome-Based Liquid Biopsy in Early Screening and Diagnosis of Cancers

    by Xuying Hao, Zihan Liu, Feifei Ma, Tuo Li, Chengbin Liu, Ning Wang, Jiebing Guan, Ningning He, Jiao Liu, Shujuan Lu, et al.

    Background: Liquid biopsy, analyzing the expression and variation of circulating tumor cell (CTC) or circulating tumor nucleic acid genes in peripheral blood, can obtain the information of tumorigenesis, metastasis and treatment, which has a potentially broader and complementary applications in the precision cancer medicine. Small vesicles, like exosomes which belongs to extracellular vesicles (EVs), which released by living cells into the vicinal surrounding biofluids, especially cells from carcinoma. Tumor-derived materials were contained by exosomes, totally including proteins, nucleic acid genes, and lipid, etcetera for instance metabolites. Besides, molecules which were synchronously belongings and carried on exosomal surface can tolerable provides crucial clues regarding their origin. Thus, classified the types of vesicles and enrich features from tissue-specific sources become presumably achieved. Therefore, exosomes and other EVs have emerged as a liquid biopsy platform for early screening and diagnosis of cancers, which constantaneously carry-over multitudinous surface molecules also throw clues regarding their origin. It is feasible to sort vesicles types, intake with approach channel to enrich the characteristics from tissue-specific origin. Based on the property that exosomes are remarkably stable in body fluids, which can amenity gathered in plasma or urine, it can be used for meticulous clinical evaluation particularly in the early stages of carcinoma. Therefore, exosomes have aroused immense interest in the study of biomarkers. Conclusions and Perspectives: This review aims to summarize the potential exosomal biomarkers especially exosomal miRNAs for exosome-based liquid biopsy in early screening and diagnostic of cancers, including lung cancer, breast cancer (BC), kidney cancer, prostate cancer (PCa), colorectal cancer (CRC), and summarizes the traditional and novel technologies for isolating exosomes and for detecting exosomal-based biomarkers, including exosomal proteins and exosomal nucleic acids. Finally, the limitations and prospects of exosome-based liquid biopsy in the early screening and diagnosis of cancers were discussed briefly.


  • Open Access

    cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro

    by Hao Sun, Yanan Du, Ming Yao, Qin Wang, Kaihua Ji, Liqing Du, Chang Xu, Ningning He, Jinhan Wang, Manman Zhang, et al.

    Tumour radioresistance is a major problem for cancer radiation therapy. To identify the underlying mechanisms of this resistance, we used human non‐small cell lung cancer (NSCLC) cell lines and focused on the Inhibitor of Apoptosis Protein (IAP) family, which contributes to tumourigenesis and chemoresistance. We investigated the possible correlation between radioresistance in six NSCLC cell lines and IAP protein levels and tested the radiosensitizing effect of birinapant in vitro, a molecule that mimics the second mitochondria‐derived activator of caspase. We found that birinapant‐induced apoptosis and inhibited the proliferation of NSCLC cells after exposure to radiation. These effects were induced by birinapant downregulation of cIAP protein levels and changes of cIAP gene expression. Overall, birinapant can inhibit tumour growth of NSCLC cell lines to ironizing radiation and act as a promising strategy to overcome radioresistance in NSCLC.


  • Open Access

    Plasma D‐Dimer Level Correlates with Age, Metastasis, Recurrence, Tumor‐Node‐Metastasis Classification (TNM), and Treatment of Non‐Small‐Cell Lung Cancer (NSCLC) Patients

    by Jiqiang Guo, Ying Gao, Zhihua Gong, Pengfei Dong, Yajie Mao, Fang Li, Jianrong Rong, Junping Zhang, Yongnian Zhou, Huijing Feng, et al.

    Objective. This study is aimed at teasing out the correlation of plasma D‐dimer (D‐D) levels to age, metastasis, TNM stage (tumor‐node‐metastasis classification), and treatment in non‐small‐cell lung cancer (NSCLC) patients of different ages, to facilitate early diagnosis of hypercoagulable state, choose appropriate treatment, and use appropriate anticoagulants. Hence, thrombosis and complications caused by excessive anticoagulants can be prevented; thrombus or disseminated intravascular coagulation (DIC) and other complications in elderly patients with NSCLC can be reduced or avoided. By monitoring the level of plasma D‐D in patients with NSCLC, recurrence and metastasis can be predicted in the early stage and the TNM stage can be evaluated. Methods. A total of 670 patients with NSCLC were selected in Shanxi Bethune Hospital from March 2014 to October 2020 as the experimental group, and 950 healthy people were selected from the physical examination center of the same hospital as the control group. The data of patients with NSCLC diagnosed for the first time without any treatment were collected and grouped based on metastasis, TNM stage, treatment, and pathological type, and the correlation with plasma D‐D level was analyzed. Plasma D‐D levels were measured by immunoturbidimetry on an ACL TOP 700 Automatic Coagulation Analyzer. The patients were further divided into two groups according to different treatment methods, and the differences in plasma D‐D levels between patients receiving chemotherapy and those receiving targeted therapy in different treatment cycles were analyzed. The correlation between D‐D levels and age in healthy controls was analyzed. The difference in D‐D levels between NSCLC patients and healthy controls of the same age was analyzed. Results. All data of both the experimental group and the control group were normally distributed. The average age of the experimental group was 61.31 ± 6.23 (range: 36‐92) years. The average age of the control group was 61.14 ± 11.12 (range: 35‐85) years. There was no significant difference in gender between the experimental group and the control group (p > 0.05). The plasma D‐D level of NSCLC patients was significantly higher than that of the healthy controls (p < 0.05). No significant difference in plasma D‐D level was found between NSCLC patients of different genders, and the finding was similar between healthy controls of different genders (p > 0.05). Significant difference in the D‐D level was found between the groups of 30‐59 years and 60‐69 years (p < 0.05), between groups of 60‐69 years and 70‐79 years (p < 0.05), and between 70‐79 years and ≥80 years (p < 0.05). The plasma D‐D level of patients ≤ 79 years old increased with age, but it decreased in those over 80 years old. According to Pearson correlation analysis, there was a positive correlation between the D‐D level and the age of NSCLC patients under 79 years old (p < 0.05). The differences in D‐D levels between the four age groups were statistically significant (p < 0.05), showing an upward trend of the D‐D level in healthy controls with the increase of age. There were statistically significant differences in D‐D levels between NSCLC patients and healthy controls of the matching age group (p < 0.05), suggesting that NSCLC patients had significantly higher D‐D levels than healthy people of the same age group. The differences in D‐D levels between NSCLC patients without metastasis, NSCLC patients with metastasis, and healthy people were statistically significant (p < 0.05). The patients with metastasis had the highest D‐D level, and healthy people had the lowest D‐D level. The difference in plasma D‐D levels between patients of different TNM stages was statistically significant (p < 0.05). Patients with an advanced TNM stage tended to have higher D‐D levels. The TNM stage and D‐D level of NSCLC patients changed significantly before and after treatment. An earlier stage was related to a more obvious change in D‐D levels after treatment with a statistically significant difference (p < 0.05). A more advanced stage was associated with a smaller change in the D‐D level after treatment, with no statistically significant difference (p > 0.05). The plasma D‐D levels before and after four cycles of chemotherapy or targeted therapy were higher than those of the healthy control group, and the differences were statistically significant (p < 0.05). The D‐D level of patients after chemotherapy was significantly lower than that before chemotherapy (p < 0.05), but there was no significant difference before and after targeted therapy (p > 0.05). The D‐D level after the first cycle of chemotherapy was higher than that before chemotherapy. The level of D‐D after the third and fourth cycles was significantly lower than that before chemotherapy (p < 0.05). No significant difference was found between the D‐D level before treatment and that after four cycles of chemotherapy (p > 0.05). Conclusion. It is suggested that coagulation test indexes should be included to evaluate the treatment regimen for NSCLC patients. Most patients with NSCLC are in a hypercoagulable state, which is related to age, tumor invasion and metastasis, recurrence, and treatment. Regular monitoring of plasma D‐D levels can facilitate early diagnosis of a hypercoagulable state and timely and appropriate use of anticoagulants, to avoid or reduce complications such as venous thromboembolism in NSCLC patients and to prevent the risk of bleeding caused by excessive anticoagulants. Clinicians can choose the treatment with less harm and maximum benefit for NSCLC patients based on the plasma D‐D level. When in a hypercoagulable state, the body’s blood viscosity increases, making it more conducive to the growth and infiltration of tumor cells. Our study shows that the recurrence and metastasis of NSCLC are related to coagulation indexes, which provides a theoretical basis for the early diagnosis and treatment of recurrent and metastatic NSCLC.